Search 

Upsher-Smith Laboratories, Inc. is pursuing improved drug therapies to improve people’s lives.  The evolution of their company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations.  Their perspective is not “more products,” but the right products that make people’s lives better.  At every level of their business, they are driven to be the best.

Upsher-Smith is actively pursuing product development opportunities in the therapeutic areas of epilepsy and Parkinson’s disease; their current product portfolio is focused in the areas of women’s health, dermatology, and cardiology.   

With a track record of successful collaboration in licensing and acquiring innovative products, Upsher-Smith is a trusted partner to many leading pharmaceutical companies, offering expertise in:   

• Conducting clinical trials to support safety and efficacy
• Preparing and managing submissions for the FDA review process
• Commercialization and distribution of products to the retail and wholesale trade
• Marketing and sales promotions through sales force, national conventions, professional advertising, and other media 

As an independent and privately held company, Upsher-Smith acts swiftly to create the right partnerships and connections that build upon their success.

On August 14, 2012, the company completed its acquisition of UK-based Proximagen Group plc, a European biotechnology company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. 

Upsher-Smith also has offices in Plymouth, MN, Denver, CO and Morristown, NJ.

“Advancing pharmacotherapy.  Improving lifeSM”….  As the company evolves, Upsher-Smith’s goal remains the same:  to assist individuals in making the best use of medicines.  This not only means producing quality pharmaceutical products, but providing access to them as well.  The company promises to provide reliable, affordable products that have a daily impact to improve lives.

Upsher-Smith’s vision is to become a leader in providing therapies that empower people suffering from central nervous system (CNS) diseases to lead healthy, productive lives.

We are a specialty pharmaceutical company intent on utilizing our proven business model of creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management.

In June 2012 we acquired Actimmune (Interferon Gamma) our first product acquisition.  Actimmune is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease and delaying time to disease progression in patients with Severe, Malignant Osteopetrosis.  

We are seeking to acquire both commercial and late stage specialty niche therapeutics.  

Vidara is a fully financed and profitable specialty pharmaceutical company.  

Viscadia is an analytically-driven management consulting firm that partners with companies in specialty pharmaceutical markets. Viscadia identifies and evaluates development, acquisition, licensing and life-cycle management opportunities. Additionally, Viscadia analyzes and optimizes the execution of specialty pharmaceutical commercial strategies. Viscadia is headquartered in San Diego, CA with a regional office in St. Louis, MO. For more information about Viscadia, email info@viscadia.com, call +1 858 496 7500 or visit www.viscadia.com.

Xcovery Vision is developing small molecule kinase inhibitors for opthamology indications. We have 4-5 canidates licensed exclusively to Xcovery Vision from Xcovery for the purpose of developing drugs for several eye diseases.

We are a spin out of Xcovery the parent oncology company founded by Sheridan Snyder founder of Genzyme and Dr. Chris Liang developer of Sutent, Pfizer's leading kidney cancer drug.

We are developing a oral drug for AMD which will be going into a Phase 1B trial this October. 

Please visit our website for more information www.xcoveryvision.com

Zosano Pharma (ZP), a spin-off of J&J, offers a fully-developed and validated transdermal drug-delivery platform to deliver small molecules, peptides, proteins and vaccines on a band-aid like patch with the efficacy of injectables.

Totally pain-free, the ZP patch offers quick onset of action, delivers with the efficacy of an injection and is stable at room temperature. It has been successfully tested with 30 compounds. The most advanced product is PTH for severe osteoporosis with completed Ph2 studies. Rights to PTH for select Asian countries have been granted to Asahi-Kasei Pharma, Japan.

ZP products are produced in its own GMP manufacturing facility at a low cost and offer attractive margins versus currently-marketed injectables.

ZP products are attractive to patients (pain-free & don't require refrigeration), payors (priced competitively versus marketed products) and pharma companies (for life cycle extension with ZP IP extending to 2027).